

[56, 54, 53, 52, 51, 50, 49, 55, 48, 47, 46, 45, 44, 62, 61, 60, 59, 57, 58, 38-42, 32, 43, 27-31, 37, 33-36, 24, 23, 25, 22, 21, 20, 19, 18, 17, 16, 15, 26, 14, 6, 5, 4, 3, 2, 8, 1, 9-13, 7]

**2009**

1. Adams, T.E., Koziolok, E.J., Hoyne, P.H., Bentley, J.D., Lu, L., Lovrecz, G., Ward, C.W., Lee, F.T., Scott, A.M., Nash, A.D., Rothacker, J., Nice, E.C., Burgess, A.W., and Johns, T.G., A truncated soluble epidermal growth factor receptor-Fc fusion ligand trap displays anti-tumour activity in vivo. *Growth Factors*, 27(3): p. 141-54 2009.
2. Herbertson, R.A., Scarsbrook, A.F., Lee, S.T., Tebbutt, N., and Scott, A.M., Established, emerging and future roles of PET/CT in the management of colorectal cancer. *Clin Radiol*, 64(3): p. 225-37 2009.
3. Gill, S., Cosolo, W., Herbertson, R.A., Berlangieri, S.U., and Scott, A.M., Medullary carcinoma of the thyroid in a patient with colon cancer and a rising carcinoembryonic antigen level. *Intern Med J*, 39(4): p. 264-5 2009.
4. Garrett, T.P., Burgess, A.W., Gan, H.K., Luwor, R.B., Cartwright, G., Walker, F., Orchard, S.G., Clayton, A.H., Nice, E.C., Rothacker, J., Catimel, B., Cavenee, W.K., Old, L.J., Stockert, E., Ritter, G., Adams, T.E., Hoyne, P.A., Wittrup, D., Chao, G., Cochran, J.R., Luo, C., Lou, M., Huyton, T., Xu, Y., Fairlie, W.D., Yao, S., Scott, A.M., and Johns, T.G., Antibodies specifically targeting a locally misfolded region of tumor associated EGFR. *Proc Natl Acad Sci U S A*, 106(13): p. 5082-7 2009.
5. Gan, H.K., Lappas, M., Cao, D.X., Cvrljevic, A., Scott, A.M., and Johns, T.G., Targeting a unique EGFR epitope with monoclonal antibody 806 activates NF-kappaB and initiates tumor vascular normalization. *J Cell Mol Med*, 2009.
6. Bauer, S., Oosterwijk-Wakka, J.C., Adrian, N., Oosterwijk, E., Fischer, E., Wuest, T., Stenner, F., Perani, A., Cohen, L., Knuth, A., Divgi, C., Jager, D., Scott, A.M., Ritter, G., Old, L.J., and Renner, C., Targeted therapy of renal cell carcinoma: synergistic activity of cG250-TNF and IFNg. *Int J Cancer*, 125(1): p. 115-23 2009.
7. Kelly, M.P., Lee, S.T., Lee, F.T., Smyth, F.E., Davis, I.D., Brechbiel, M.W., and Scott, A.M., Therapeutic efficacy of <sup>177</sup>Lu-CHX-A"-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy. *Prostate*, 69(1): p. 92-104 2009.
8. Lee, S.T., Ghanem, M., Herbertson, R.A., Berlangieri, S.U., Byrne, A.J., Tabone, K., Mitchell, P., Knight, S.R., Feigen, M., and Scott, A.M., Prognostic Value of (18)F-FDG PET/CT in Patients with Malignant Pleural Mesothelioma. *Mol Imaging Biol*, 2009.
9. Westwood, J.A., Murray, W.K., Trivett, M., Haynes, N.M., Solomon, B., Mileskin, L., Ball, D., Michael, M., Burman, A., Mayura-Guru, P., Trapani, J.A., Peinert, S., Honemann, D., Miles Prince, H., Scott, A.M., Smyth, M.J., Darcy, P.K., and Kershaw, M.H., The Lewis-Y carbohydrate antigen is expressed by many human tumors and can serve as a target for genetically redirected T cells despite the presence of soluble antigen in serum. *J Immunother*, 32(3): p. 292-301 2009.

10. Scott, A.M., Gunawardana, D.H., Wong, J., Kirkwood, I., Hicks, R.J., Ho Shon, I., Ramshaw, J.E., and Robins, P., Positron emission tomography changes management, improves prognostic stratification and is superior to gallium scintigraphy in patients with low-grade lymphoma: results of a multicentre prospective study. *Eur J Nucl Med Mol Imaging*, 36(3): p. 347-53 2009.
11. Pillay, V., Allaf, L., Wilding, A.L., Donoghue, J.F., Court, N.W., Greenall, S.A., Scott, A.M., and Johns, T.G., The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases. *Neoplasia*, 11(5): p. 448-58, 2 p following 458 2009.
12. Olver, J.S., O'keefe, G., Jones, G.R., Burrows, G.D., Tochon-Danguy, H.J., Ackermann, U., Scott, A., and Norman, T.R., Dopamine D(1) receptor binding in the striatum of patients with obsessive-compulsive disorder. *J Affect Disord*, 114(1-3): p. 321-6 2009.
13. Macfarlane, D., Socrates, A., Eisenberg, P., Larcos, G., Roach, P., Gerometta, M., Smart, R., Tsui, W., and Scott, A.M., Imaging of deep venous thrombosis in patients using a radiolabelled anti-D-dimer Fab' fragment (99mTc-DI-DD3B6/22-80B3): results of a phase I trial. *Eur J Nucl Med Mol Imaging*, 36(2): p. 250-9 2009.

---

## 2008

14. Chatterton, B.E., Ho Shon, I., Baldey, A., Lenzo, N., Patrikeos, A., Kelley, B., Wong, D., Ramshaw, J.E., and Scott, A.M., Positron emission tomography changes management and prognostic stratification in patients with oesophageal cancer: results of a multicentre prospective study. *Eur J Nucl Med Mol Imaging*, 2008.
15. Kelly, M.P., Lee, F.T., Tahtis, K., Power, B.E., Smyth, F.E., Brechbiel, M.W., Hudson, P.J., and Scott, A.M., Tumor targeting by a multivalent single-chain Fv (scFv) anti-Lewis Y antibody construct. *Cancer Biother Radiopharm*, 23(4): p. 411-23 2008.
16. Kelly, M.P., Lee, S.T., Lee, F.T., Smyth, F.E., Davis, I.D., Brechbiel, M.W., and Scott, A.M., Therapeutic efficacy of (177)Lu-CHX-A"-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy. *Prostate*, 2008.
17. Lee, S.T., Tan, T., Poon, A.M., Toh, H.B., Gill, S., Berlangieri, S.U., Kraft, E., Byrne, A.J., Pathmaraj, K., O'keefe, G.J., Tebbutt, N., and Scott, A.M., Role of low-dose, noncontrast computed tomography from integrated Positron Emission Tomography/Computed Tomography in evaluating incidental 2-Deoxy-2-[F-18]fluoro-D: -glucose-avid colon lesions. *Mol Imaging Biol*, 10(1): p. 48-53 2008.
18. Macfarlane, D., Socrates, A., Eisenberg, P., Larcos, G., Roach, P., Gerometta, M., Smart, R., Tsui, W., and Scott, A.M., Imaging of deep venous thrombosis in patients using a radiolabelled anti-D-dimer Fab' fragment ((99m)Tc-DI-DD3B6/22-80B3): results of a phase I trial. *Eur J Nucl Med Mol Imaging*, 2008.
19. Nguyen, B.T., Joon, D.L., Khoo, V., Quong, G., Chao, M., Wada, M., Joon, M.L., See, A., Feigen, M., Rykers, K., Kai, C., Zupan, E., and Scott, A., Assessing the impact of FDG-PET in the management of anal cancer. *Radiother Oncol*, 87(3): p. 376-82 2008.

20. Scott, A. and Lee, S.T., *Clinical Radionuclide Therapy*, in *Targeted Radionuclide Tumor Therapy - Biological Aspects*, T. Stigbrand, J. Carlsson, and G. Adams, Editors. 2008, Springer. p. 349-385.
21. Scott, A.M., Gunawardana, D.H., Bartholomeusz, D., Ramshaw, J.E., and Lin, P., PET changes management and improves prognostic stratification in patients with head and neck cancer: Results of a multicenter prospective study. *J Nucl Med*, 49(10): p. 1593-1600 2008.
22. Scott, A.M., Gunawardana, D.H., Kelley, B., Stuckey, J.G., Byrne, A.J., Ramshaw, J.E., and Fulham, M.J., PET changes management and improves prognostic stratification in patients with recurrent colorectal cancer: results of a multicenter prospective study. *J Nucl Med*, 49(9): p. 1451-7 2008.
23. Scott, A.M., Gunawardana, D.H., Wong, J., Kirkwood, I., Hicks, R.J., Ho Shon, I., Ramshaw, J.E., and Robins, P., Positron emission tomography changes management, improves prognostic stratification and is superior to gallium scintigraphy in patients with low-grade lymphoma: results of a multicentre prospective study. *Eur J Nucl Med Mol Imaging*, 2008.
24. Herbertson, R.A., Scarsbrook, A.F., Lee, S.T., Tebbutt, N., and Scott, A.M., Established, emerging and future roles of PET/CT in the management of colorectal cancer. *Clin Radiol*, 2008.
25. Westwood, J.A., Murray, W.K., Trivett, M., Shin, A., Neeson, P., Macgregor, D.P., Haynes, N.M., Trapani, J.A., Mayura-Guru, P., Fox, S., Peinert, S., Honemann, D., Prince, H.M., Ritchie, D., Scott, A.M., Smyth, F.E., Smyth, M.J., Darcy, P.K., and Kershaw, M.H., Absence of retroviral vector-mediated transformation of gene-modified T cells after long-term engraftment in mice. *Gene Ther*, 15(14): p. 1056-66 2008.
26. Kageyama, S., Kitano, S., Hirayama, M., Nagata, Y., Imai, H., Shiraishi, T., Akiyoshi, K., Scott, A.M., Murphy, R., Hoffman, E.W., Old, L.J., Katayama, N., and Shiku, H., Humoral immune responses in patients vaccinated with 1-146 HER2 protein complexed with cholesteryl pullulan nanogel. *Cancer Sci*, 99(3): p. 601-7 2008.

---

## 2007

27. Cortez, C., Tomaskovic-Crook, E., Johnston, A.P.R., Scott, A.M., Nice, E.C., Heath, J.K., and Caruso, F., Influence of Size, Surface, Cell Line, and Kinetic Properties on the Specific Binding of A33 Antigen-Targeted Multilayered Particles and Capsules to Colorectal Cancer Cells *ACS Nano*, 1(2): p. 93-102 2007.
28. Davis, I.D., Liu, Z., Saunders, W., Lee, F.T., Spirkoska, V., Hopkins, W., Smyth, F.E., Chong, G., Papenfuss, A.T., Chappell, B., Poon, A., Saunderson, T.H., Hoffman, E.W., Old, L.J., and Scott, A.M., A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma. *Cancer Immun*, 7: p. 14 2007.
29. Davis, I.D., Wiseman, G.A., Lee, F.T., Gansen, D.N., Hopkins, W., Papenfuss, A.T., Liu, Z., Moynihan, T.J., Croghan, G.A., Adjei, A.A., Hoffman, E.W., Ingle, J.N., Old, L.J., and Scott, A.M., A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma. *Cancer Immun*, 7: p. 13 2007.

30. Gan, H.K., Walker, F., Burgess, A.W., Rigopoulos, A., Scott, A.M., and Johns, T.G., The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor AG1478 increases the formation of inactive untethered EGFR dimers. Implications for combination therapy with monoclonal antibody 806. *J Biol Chem*, 282(5): p. 2840-50 2007.
31. Herbertson, R., Lee, S., Tebbutt, N., and Scott, A., The expanding role of PET technology in the management of patients with colorectal cancer. *Ann Oncol*, 2007.
32. Scott, A.M., Tebbutt, N., Lee, F.T., Cavicchiolo, T., Liu, Z., Gill, S., Poon, A.M., Hopkins, W., Smyth, F.E., Murone, C., Macgregor, D., Papenfuss, A.T., Chappell, B., Saunder, T.H., Brechbiel, M.W., Davis, I.D., Murphy, R., Chong, G., Hoffman, E.W., and Old, L.J., A Phase I Biodistribution and Pharmacokinetic Trial of Humanized Monoclonal Antibody Hu3s193 in Patients with Advanced Epithelial Cancers that Express the Lewis-Y Antigen. *Clin Cancer Res*, 13(11): p. 3286-92 2007.
33. Kageyama, S., Kitano, S., Hirayama, M., Nagata, Y., Imai, H., Shiraishi, T., Akiyoshi, K., Scott, A.M., Murphy, R., Hoffman, E.W., Old, L.J., Katayama, N., and Shiku, H., Humoral immune responses in patients vaccinated with 1-146 HER2 protein complexed with cholesteryl pullulan nanogel. *Cancer Sci*, 2007.
34. Kelly, M.P., Lee, F.T., Tahtis, K., Smyth, F.E., Brechbiel, M.W., and Scott, A.M., Radioimmunotherapy with {alpha}-Particle Emitting <sup>213</sup>Bi-C-Functionalized trans-Cyclohexyl-Diethylenetriaminepentaacetic Acid-Humanized 3S193 Is Enhanced by Combination with Paclitaxel Chemotherapy. *Clin Cancer Res*, 13(18): p. 5604s-5612s 2007.
35. Krug, L.M., Milton, D.T., Jungbluth, A.A., Chen, L.C., Quaia, E., Pandit-Taskar, N., Nagel, A., Jones, J., Kris, M.G., Finn, R., Smith-Jones, P., Scott, A.M., Old, L., and Divgi, C., Targeting Lewis Y (Le(y)) in small cell lung cancer with a humanized monoclonal antibody, hu3S193: a pilot trial testing two dose levels. *J Thorac Oncol*, 2(10): p. 947-52 2007.
36. Lawrentschuk, N., Bolton, D.M., Davis, I.D., and Scott, A.M., Renal Cell Cancer and Positron Emission Tomography- an evolving diagnostic and therapeutic relationship. *Current Medical Imaging Reviews*, 3(1): p. 17-26 2007.
37. Lee, S.T. and Scott, A.M., Hypoxia positron emission tomography imaging with (18)f-fluoromisonidazole. *Semin Nucl Med*, 37(6): p. 451-61 2007.
38. Lawrentschuk, N., Davis, I.D., Bolton, D.M., and Scott, A.M., Diagnostic and therapeutic use of radioisotopes for bony disease in prostate cancer: current practice. *Int J Urol*, 14(2): p. 89-95 2007.
39. Lee, S.T., Berlangieri, S.U., Poon, A.M., Mitchell, P., Pathmaraj, K., Tabone, K., Byrne, A.J., O'keefe G, J., Knight, S.R., Clarke, C.P., and Scott, A.M., Prevalence of occult metastatic disease in patients undergoing F-FDG PET for primary diagnosis or staging of lung carcinoma and solitary pulmonary nodules. *Intern Med J*, 2007.
40. Li, D., Ji, H., Zaghlul, S., Mcnamara, K., Liang, M.C., Shimamura, T., Kubo, S., Takahashi, M., Chirieac, L.R., Padera, R.F., Scott, A.M., Jungbluth, A.A., Cavenee, W.K., Old, L.J., Demetri, G.D., and Wong, K.K., Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas. *J Clin Invest*, 117(2): p. 346-52 2007.

41. Perera, R.M., Zoncu, R., Johns, T.G., Pypaert, M., Lee, F.T., Mellman, I., Old, L.J., Toomre, D.K., and Scott, A.M., Internalization, intracellular trafficking, and biodistribution of monoclonal antibody 806: a novel anti-epidermal growth factor receptor antibody. *Neoplasia*, 9(12): p. 1099-110 2007.
42. Scott, A.M., Lee, F.T., Tebbutt, N., Herbertson, R., Gill, S.S., Liu, Z., Skrinos, E., Murone, C., Saunder, T.H., Chappell, B., Papenfuss, A.T., Poon, A.M., Hopkins, W., Smyth, F.E., Macgregor, D., Cher, L.M., Jungbluth, A.A., Brechbiel, M.W., Murphy, R., Burgess, A.W., Hoffman, E.W., Johns, T.G., and Old, L.J., A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. *Proc Natl Acad Sci U S A*, 104(10): p. 4071-6 2007.
43. Johns, T.G., Perera, R.M., Vernes, S.C., Vitali, A.A., Cao, D.X., Cavenee, W.K., Scott, A.M., and Furnari, F.B., The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization. *Clin Cancer Res*, 13(6): p. 1911-25 2007.

---

## 2006

44. Lawrentschuk, N., Davis, I.D., Bolton, D.M., and Scott, A.M., Positron emission tomography and molecular imaging of the prostate: an update. *BJU Int*, 97(5): p. 923-31 2006.
45. Lawrentschuk, N., Poon, A.M., and Scott, A.M., Fluorine-18 fluorothymidine: a new positron emission radioisotope for renal tumors. *Clin Nucl Med*, 31(12): p. 788-9 2006.
46. Lawrentschuk, N., Rigopoulos, A., Lee, F.T., Davis, I.D., Scott, A.M., and Bolton, D.M., Xenografting tumour beneath the renal capsule using modern surgical equipment. *Eur Surg Res*, 38(3): p. 340-6 2006.
47. Macfarlane, D.J., Smart, R.C., Tsui, W.W., Gerometta, M., Eisenberg, P.R., and Scott, A.M., Safety, pharmacokinetic and dosimetry evaluation of the proposed thrombus imaging agent (99m)Tc-DI-DD-3B6/22-80B3 Fab'. *Eur J Nucl Med Mol Imaging*, 33(6): p. 648-656 2006.
48. Michael, M., Thompson, M., Hicks, R.J., Mitchell, P.L., Ellis, A., Milner, A.D., Di Iulio, J., Scott, A.M., Gurtler, V., Hoskins, J.M., Clarke, S.J., Tebbutt, N.C., Foo, K., Jefford, M., and Zalcborg, J.R., Relationship of hepatic functional imaging to irinotecan pharmacokinetics and genetic parameters of drug elimination. *J Clin Oncol*, 24(26): p. 4228-35 2006.
49. Sakamoto, J., Oriuchi, N., Mochiki, E., Asao, T., Scott, A.M., Hoffman, E.W., Jungbluth, A.A., Matsui, T., Lee, F.T., Papenfuss, A., Kuwano, H., Takahashi, T., Endo, K., and Old, L.J., A phase I radioimmunolocalization trial of humanized monoclonal antibody huA33 in patients with gastric carcinoma. *Cancer Sci*, 97(11): p. 1248-54 2006.
50. Belhocine, T.Z., Scott, A.M., Even-Sapir, E., Urbain, J.L., and Essner, R., Role of nuclear medicine in the management of cutaneous malignant melanoma. *J Nucl Med*, 47(6): p. 957-67 2006.

51. Cebon, J., Findlay, M., Hargreaves, C., Stockler, M., Thompson, P., Boyer, M., Roberts, S., Poon, A., Scott, A.M., Kalff, V., Garas, G., Dowling, A., Crawford, D., Ring, J., Basser, R., Strickland, A., Macdonald, G., Green, M., Nowak, A., Dickman, B., Dhillon, H., and GebSKI, V., Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide. *Br J Cancer*, 95(7): p. 853-61 2006.
52. Cher, L.M., Murone, C., Lawrentschuk, N., Ramdave, S., Papenfuss, A., Hannah, A., O'keefe, G.J., Sachinidis, J.I., Berlangieri, S.U., Fabinyi, G., and Scott, A.M., Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies. *J Nucl Med*, 47(3): p. 410-8 2006.
53. Cherk, M.H., Foo, S.S., Poon, A.M., Knight, S.R., Murone, C., Papenfuss, A.T., Sachinidis, J.I., Saunder, T.H., O'keefe, G.J., and Scott, A.M., Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-Fluoromisonidazole and 18F-FDG PET. *J Nucl Med*, 47(12): p. 1921-6 2006.
54. Cortez, C., Tomaskovic-Crook, E., Johnston, A.P., Radt, B., Cody, S.H., Scott, A., Nice, E.C., Heath, J.K., and Caruso, F., Targeting and Uptake of Multilayered Particles to Colorectal Cancer Cells. *Adv.Mater.*, 18: p. 1998-2003 2006.
55. Kitano, S., Kageyama, S., Nagata, Y., Miyahara, Y., Hiasa, A., Naota, H., Okumura, S., Imai, H., Shiraishi, T., Masuya, M., Nishikawa, M., Sunamoto, J., Akiyoshi, K., Kanematsu, T., Scott, A.M., Murphy, R., Hoffman, E.W., Old, L.J., and Shiku, H., HER2-specific T-cell immune responses in patients vaccinated with truncated HER2 protein complexed with nanogels of cholesteryl pullulan. *Clin Cancer Res*, 12(24): p. 7397-405 2006.
56. Ellis, A.G., Doherty, M.M., Walker, F., Weinstock, J., Nerrie, M., Vitali, A., Murphy, R., Johns, T.G., Scott, A.M., Levitzki, A., Mclachlan, G., Webster, L.K., Burgess, A.W., and Nice, E.C., Preclinical analysis of the analinoquinazoline AG1478, a specific small molecule inhibitor of EGF receptor tyrosine kinase. *Biochem Pharmacol*, 71(10): p. 1422-34 2006.
57. Falzon, C.L., Ackermann, U., Spratt, N., Tochon-Danguy, H.J., White, J., Howells, D., and Scott, A.M., F-18 labelled N,N-Bis-haloethylamino-phenylsulfoxides - A new class of compounds for the imaging of hypoxic tissue. *J Label Compd Radiopharm*, 49: p. 1089-1103 2006.
58. Essner, R., Belhocine, T., Scott, A.M., and Even-Sapir, E., Novel imaging techniques in melanoma. *Surg Oncol Clin N Am*, 15(2): p. 253-83 2006.
59. Gan, H.K., Walker, F., Burgess, A.W., Rigopoulos, A., Scott, A.M., and Johns, T.G., The EGFR tyrosine kinase inhibitor AG1478 increases the formation of inactive untethered EGFR dimers: Implications for combination therapy with mab 806. *J Biol Chem*, Nov 8; [Epub ahead of print] 2006.
60. Harrison, B.J., Yucel, M., Shaw, M., Kyrios, M., Maruff, P., Brewer, W.J., Purcell, R., Velakoulis, D., Strother, S.C., Scott, A.M., Nathan, P.J., and Pantelis, C., Evaluating brain activity in obsessive-compulsive disorder: preliminary insights from a multivariate analysis. *Psychiatry Res*, 147(2-3): p. 227-31 2006.

61. Kelly, M.P., Lee, F.T., Smyth, F.E., Brechbiel, M.W., and Scott, A.M., Enhanced efficacy of <sup>90</sup>Y-radiolabeled anti-Lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model. *J Nucl Med*, 47(4): p. 716-25 2006.
62. Lawrentschuk, N., Davis, I.D., Bolton, D.M., and Scott, A.M., Positron emission tomography (PET), immuno-PET and radioimmunotherapy in renal cell carcinoma: a developing diagnostic and therapeutic relationship. *BJU Int*, 97(5): p. 916-22 2006.

---

**2005**

63. Westwood, J.A., Smyth, M.J., Teng, M.W., Moeller, M., Trapani, J.A., Scott, A.M., Smyth, F.E., Cartwright, G.A., Power, B.E., Honemann, D., Prince, H.M., Darcy, P.K., and Kershaw, M.H., Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. *Proc Natl Acad Sci U S A*, 102(52): p. 19051-6 2005.
64. Vearing, C., Lee, F.T., Wimmer-Kleikamp, S., Spirkoska, V., To, C., Stylianou, C., Spanevello, M., Brechbiel, M., Boyd, A.W., Scott, A.M., and Lackmann, M., Concurrent binding of anti-EphA3 antibody and ephrin-A5 amplifies EphA3 signaling and downstream responses: potential as EphA3-specific tumor-targeting reagents. *Cancer Res*, 65(15): p. 6745-54 2005.
65. Scott, A.M., Liu, Z., Murone, C., Johns, T.G., Macgregor, D., Smyth, F.E., Lee, F.T., Cebon, J., Davis, I.D., Hopkins, W., Mountain, A.J., Rigopoulos, A., Hanai, N., and Old, L.J., Immunological effects of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma. *Cancer Immun*, 5: p. 3 2005.
66. Scott, A.M., Lee, F.T., Jones, R., Hopkins, W., Macgregor, D., Cebon, J.S., Hannah, A., Chong, G., U, P., Papenfuss, A., Rigopoulos, A., Sturrock, S., Murphy, R., Wirth, V., Murone, C., Smyth, F.E., Knight, S., Welt, S., Ritter, G., Richards, E., Nice, E.C., Burgess, A.W., and Old, L.J., A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake. *Clin Cancer Res*, 11(13): p. 4810-7 2005.
67. Scott, A.M., Radioimmunotherapy of prostate cancer: does tumor size matter? *J Clin Oncol*, 23(21): p. 4567-9 2005.
68. Perera, R.M., Narita, Y., Furnari, F.B., Gan, H.K., Murone, C., Ahlkvist, M., Luwor, R.B., Burgess, A.W., Stockert, E., Jungbluth, A.A., Old, L.J., Cavenee, W.K., Scott, A.M., and Johns, T.G., Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity. *Clin Cancer Res*, 11(17): p. 6390-9 2005.
69. Panousis, C., Rayzman, V.M., Johns, T.G., Renner, C., Liu, Z., Cartwright, G., Lee, F.T., Wang, D., Gan, H., Cao, D., Kypridis, A., Smyth, F.E., Brechbiel, M.W., Burgess, A.W., Old, L.J., and Scott, A.M., Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR. *Br J Cancer*, 92(6): p. 1069-77 2005.
70. Murphy, R., Green, S., Ritter, G., Cohen, L., Ryan, D., Woods, W., Rubira, M., Cebon, J., Davis, I.D., Sjolander, A., Kypridis, A., Kalnins, H., Mcnamara, M., Moloney, M.B., Ackland, J., Cartwright, G., Rood, J., Dumsday, G., Healey, K., Maher, D., Maraskovsky, E., Chen, Y.T., Hoffman, E.W., Old, L.J., and Scott, A.M., Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditions. *Prep Biochem Biotechnol*, 35(2): p. 119-34 2005.

71. Lee, F.T., Mountain, A.J., Kelly, M.P., Hall, C., Rigopoulos, A., Johns, T.G., Smyth, F.E., Brechbiel, M.W., Nice, E.C., Burgess, A.W., and Scott, A.M., Enhanced efficacy of radioimmunotherapy with <sup>90</sup>Y-CHX-A"-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478. *Clin Cancer Res*, 11(19 Pt 2): p. 7080s-7086s 2005.
72. Lawrentschuk, N., Poon, A.M., Foo, S.S., Putra, L.G., Murone, C., Davis, I.D., Bolton, D.M., and Scott, A.M., Assessing regional hypoxia in human renal tumours using <sup>18</sup>F-fluoromisonidazole positron emission tomography. *BJU Int*, 96(4): p. 540-6 2005.
73. Johns, T.G., Mellman, I., Cartwright, G.A., Ritter, G., Old, L.J., Burgess, A.W., and Scott, A.M., The antitumor monoclonal antibody 806 recognizes a high-mannose form of the EGF receptor that reaches the cell surface when cells over-express the receptor. *Faseb J*, 19(7): p. 780-2 2005.
74. Chong, G., Lee, F.T., Hopkins, W., Tebbutt, N., Cebon, J.S., Mountain, A.J., Chappell, B., Papenfuss, A., Schleyer, P., U, P., Murphy, R., Wirth, V., Smyth, F.E., Potasz, N., Poon, A., Davis, I.D., Saunderson, T., O'keefe G, J., Burgess, A.W., Hoffman, E.W., Old, L.J., and Scott, A.M., Phase I trial of <sup>131</sup>I-huA33 in patients with advanced colorectal carcinoma. *Clin Cancer Res*, 11(13): p. 4818-26 2005.
75. Ackermann, U., Tochon-Danguy, H.J., Nerrie, M., Nice, E.C., Sachinidis, J.I., and Scott, A.M., Synthesis, <sup>11</sup>C labeling and biological properties of derivatives of the tyrostatin AG957. *Nucl Med Biol*, 32(4): p. 323-8 2005.

---

## 2004

76. Walker, F., Orchard, S.G., Jorissen, R.N., Hall, N.E., Zhang, H.H., Hoyne, P.A., Adams, T.E., Johns, T.G., Ward, C., Garrett, T.P., Zhu, H.J., Nerrie, M., Scott, A.M., Nice, E.C., and Burgess, A.W., CR1/CR2 interactions modulate the functions of the cell surface epidermal growth factor receptor. *J Biol Chem*, 279(21): p. 22387-98 2004.
77. Ramsland, P.A., Farrugia, W., Bradford, T.M., Mark Hogarth, P., and Scott, A.M., Structural convergence of antibody binding of carbohydrate determinants in Lewis Y tumor antigens. *J Mol Biol*, 340(4): p. 809-18 2004.
78. Luwor, R.B., Zhu, H.J., Walker, F., Vitali, A.A., Perera, R.M., Burgess, A.W., Scott, A.M., and Johns, T.G., The tumor-specific de2-7 epidermal growth factor receptor (EGFR) promotes cells survival and heterodimerizes with the wild-type EGFR. *Oncogene*, 23(36): p. 6095-104 2004.
79. Kloft, C., Graefe, E.U., Tanswell, P., Scott, A.M., Hofheinz, R., Amelsberg, A., and Karlsson, M.O., Population pharmacokinetics of sibrutumab, a novel therapeutic monoclonal antibody, in cancer patients. *Invest New Drugs*, 22(1): p. 39-52 2004.
80. Johns, T.G., Adams, T.E., Cochran, J.R., Hall, N.E., Hoyne, P.A., Olsen, M.J., Kim, Y.S., Rothacker, J., Nice, E.C., Walker, F., Ritter, G., Jungbluth, A.A., Old, L.J., Ward, C.W., Burgess, A.W., Wittrup, K.D., and Scott, A.M., Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor. *J Biol Chem*, 279(29): p. 30375-84 2004.
81. Bauer, S., Adrian, N., Williamson, B., Panousis, C., Fadle, N., Smerd, J., Fettah, I., Scott, A.M., Pfreundschuh, M., and Renner, C., Targeted bioactivity of membrane-anchored TNF by an antibody-derived TNF fusion protein. *J Immunol*, 172(6): p. 3930-9 2004.